Boston Scientific Corporation (NYSE:BSX) EVP Michael P. Phalen sold 15,500 shares of the business’s stock in a transaction dated Tuesday, August 29th. The stock was sold at an average price of $26.87, for a total transaction of $416,485.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Michael P. Phalen also recently made the following trade(s):

  • On Monday, July 31st, Michael P. Phalen sold 15,500 shares of Boston Scientific Corporation stock. The stock was sold at an average price of $27.13, for a total transaction of $420,515.00.
  • On Thursday, June 29th, Michael P. Phalen sold 15,500 shares of Boston Scientific Corporation stock. The stock was sold at an average price of $28.02, for a total transaction of $434,310.00.

Shares of Boston Scientific Corporation (NYSE:BSX) opened at 27.55 on Friday. Boston Scientific Corporation has a 12-month low of $19.67 and a 12-month high of $28.51. The company has a market cap of $37.80 billion, a P/E ratio of 49.28 and a beta of 1.09. The firm has a 50-day moving average of $27.02 and a 200-day moving average of $26.28.

Boston Scientific Corporation (NYSE:BSX) last posted its earnings results on Thursday, July 27th. The medical equipment provider reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.31 by $0.01. The firm had revenue of $2.26 billion during the quarter, compared to the consensus estimate of $2.21 billion. Boston Scientific Corporation had a net margin of 9.04% and a return on equity of 23.62%. The company’s revenue was up 6.2% on a year-over-year basis. During the same quarter last year, the company earned $0.27 earnings per share. Analysts predict that Boston Scientific Corporation will post $1.26 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Michael P. Phalen Sells 15,500 Shares of Boston Scientific Corporation (BSX) Stock” was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another site, it was copied illegally and reposted in violation of United States & international trademark and copyright law. The correct version of this article can be read at https://www.watchlistnews.com/michael-p-phalen-sells-15500-shares-of-boston-scientific-corporation-bsx-stock/1535577.html.

BSX has been the topic of several recent analyst reports. Needham & Company LLC boosted their price objective on shares of Boston Scientific Corporation from $30.00 to $32.00 and gave the stock a “buy” rating in a research note on Thursday, June 22nd. BMO Capital Markets restated a “buy” rating and set a $30.00 price objective on shares of Boston Scientific Corporation in a research note on Wednesday, June 21st. Zacks Investment Research upgraded shares of Boston Scientific Corporation from a “hold” rating to a “buy” rating and set a $31.00 price objective on the stock in a research note on Wednesday, June 28th. BidaskClub lowered shares of Boston Scientific Corporation from a “strong-buy” rating to a “buy” rating in a research note on Thursday, July 6th. Finally, Royal Bank Of Canada restated a “buy” rating and set a $31.00 price objective on shares of Boston Scientific Corporation in a research note on Wednesday, July 12th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Boston Scientific Corporation currently has an average rating of “Buy” and an average price target of $30.06.

Institutional investors have recently bought and sold shares of the company. DekaBank Deutsche Girozentrale boosted its position in shares of Boston Scientific Corporation by 50.5% in the first quarter. DekaBank Deutsche Girozentrale now owns 317,348 shares of the medical equipment provider’s stock valued at $7,855,000 after buying an additional 106,533 shares in the last quarter. Diamond Hill Capital Management Inc. boosted its position in shares of Boston Scientific Corporation by 0.3% in the first quarter. Diamond Hill Capital Management Inc. now owns 3,361,258 shares of the medical equipment provider’s stock valued at $83,594,000 after buying an additional 9,850 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. boosted its position in shares of Boston Scientific Corporation by 0.3% in the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 4,026,475 shares of the medical equipment provider’s stock valued at $100,138,000 after buying an additional 12,586 shares in the last quarter. State Treasurer State of Michigan boosted its position in shares of Boston Scientific Corporation by 0.6% in the first quarter. State Treasurer State of Michigan now owns 447,896 shares of the medical equipment provider’s stock valued at $11,139,000 after buying an additional 2,600 shares in the last quarter. Finally, Commerzbank Aktiengesellschaft FI boosted its position in shares of Boston Scientific Corporation by 39.6% in the first quarter. Commerzbank Aktiengesellschaft FI now owns 31,506 shares of the medical equipment provider’s stock valued at $784,000 after buying an additional 8,939 shares in the last quarter. Hedge funds and other institutional investors own 90.52% of the company’s stock.

Boston Scientific Corporation Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Insider Buying and Selling by Quarter for Boston Scientific Corporation (NYSE:BSX)

Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.